[1]潘 静,王艳翚.区域差异化背景下我国23个省市药价水平比较分析[J].卫生经济研究,2019,(02):49-52.
　PAN Jing,WANG Yan-hui.Comparative Analysis of Drug Price Levels in 23 Provinces and Cities in China under the Background of Regional Differentiation[J].Journal Press of Health Economics Research,2019,(02):49-52.
点击复制

区域差异化背景下我国23个省市药价水平比较分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年02期
页码:
49-52
栏目:
价格与补偿
出版日期:
2019-02-01

文章信息/Info

Title:
Comparative Analysis of Drug Price Levels in 23 Provinces and Cities in China under the Background of Regional Differentiation
作者:
潘 静1; 王艳翚1
1.南京中医药大学，江苏 南京 210023
Author(s):
PAN Jing; WANG Yan-hui
Nanjing University of Chinese Medicine, NanJing Jiangsu 210023, China
关键词:
药价改革; 药品价格; 药品集中招标采购; 差别化定价
Keywords:
Drug price reform;  drug prices;  centralized drug bidding;  differential pricing
分类号:
R19
文献标志码:
A
摘要:
目的：探讨我国各省市药品价格水平的差异，提出药价治理的对策建议。方法：从差别化定价视角，分析我国23个省市药品价格水平差异，及其与地区经济发展水平的相适性，并分析原因。结果：除上海市外，其他大多数地区药价水平与经济发展水平不平衡，经济发展水平较落后的地区药价水平却相对更高。结论：我国药品的定价机制应考虑区域经济发展水平的差异性，形成差别化定价，从而完善药价治理体系。
Abstract:
Objective To explore the differences in drug price levels in various provinces and cities in China, and to propose countermeasures for drug price management. Methods From the perspective of differential pricing, this paper analyzed the differences in drug price levels in 23 provinces and cities in China, and their compatibility with regional economic development levels. Results Except for Shanghai, the compatibility between drug prices and economic development levels was poor. Regions with low economic development levels reported higher drug prices. Conclusion The pricing mechanism of Chinese medicines should take into account the differences in regional economic development levels and form differentiated pricing, thus to improve the drug price management system.

参考文献/References:

[1] Kaiser U, Mendez SJ.How Do Drug Prices Respond to a Change from External to Internal Reference Pricing?Evidence from a Danish Regulatory Reform[J].Zew Discussion Papers, 2015.
[2] Danzon, P M, A W Mulcahy, A K Towse.Pharmaceutical Pricing in Emerging Markets:Effects of Income, Competition, and Procurement[J].Health Economics, 2015, 24 (2) :238-252.
[3] Dumoulin, J.Global Pricing Strategies for Innovative Essential Drugs[J].International Journal of Biotechnology, 2001, 3 (3/4) :338-349.
[4] Vernon, J A.Examining the Link between Price Regulation and Pharmaceutical R&D Investment[J].Health Economics, 2005, 14 (1) :1-16.
[5] Maloney MT, Civan A.The Effect of Price on Pharmaceutical R&D[J].B.e.journal of Economic Analysis&Policy, 2009, 9 (1) .
[6] 陈云凡.基本药物“零差价”管制政策效果评估[J].探索,2017(2):86-92.
[7] 李永强.市场分割、渠道控制与药品市场价格形成机制[J].卫生经济研究,2017(3):12-14.
[8] 马蓉,汤少梁,冯莉钧.药品价格多方谈判主体及其事权划分研究[J].卫生经济研究,2017(3):8-11.
[9] 史武男,杨秀云.我国药价水平能实现可及性和创新激励性吗?[J].现代经济探讨,2018(5):22-29.
[10] 崔啸天,傅鸿鹏,刘昉.新一轮药品集中采购价格10省份间对比研究[J].中国医院管理,2018,38(1):62-66.
[11] 赵彦云,王雪琪.我国居民消费价格空间指数探讨和实证研究[J].调研世界,2015(12):41-46.
[12] 马芳芳,吴晶.药品价格指数的方法学综述[J].中国卫生政策研究,2015,8(7):61-67.
[13] 郭丽岩.完善中国药品器械招标采购的思路与对策[J].经济研究参考,2014(32):67-86.
[14] 陈桂生,刘梦琦.基于利益博弈的药品价格规制问题研究[J].价格月刊,2018(5):7-14.
[15] 李海艳. 药品价格监管的行政法问题研究[D].中国政法大学,2011.

相似文献/References:

[1]周引德,傅鸿鹏.基层医疗机构药品配备使用情况分析[J].卫生经济研究,2016,(05):38.
[2]赵 静.药品价格改革问题研究[J].卫生经济研究,2016,(07):51.
[3]李银才.药品价格市场形成机制改革研究[J].卫生经济研究,2016,(07):55.
[4]黄泽华,潘 越,钭江苑,等.药物经济学在医保决策中的应用[J].卫生经济研究,2017,(03):37.
[5]胡善联.药品购销“两票制”政策的理论和实践[J].卫生经济研究,2017,(04):8.
[6]乔家骏,曾旖旎,傅鸿鹏.“两票制”对药企经济运行及药品价格的影响[J].卫生经济研究,2018,(10):61.
　QIAO Jia-jun,ZENG Yi-ni,FU Hong-peng.The Influence of “Two-vote System” on the Economic Operation of Pharmaceutical Companies and Drug Prices[J].Journal Press of Health Economics Research,2018,(02):61.
[7]吴 天.药品集中采购价格与药品费用控制研究[J].卫生经济研究,2018,(12):32.
　WU Tian.Research on Centralized Purchasing Price and Drug Cost Control of Medicines[J].Journal Press of Health Economics Research,2018,(02):32.
[8]殷 婷,汤少梁.基于消费者剩余理论的患者药品福利研究[J].卫生经济研究,2019,(02):13.
　YIN Ting,TANG Shao-liang.Research on Patient Drug Welfare Based on Consumer Surplus Theory[J].Journal Press of Health Economics Research,2019,(02):13.
[9]舒 茜,姚峥嵘,王艳翚,等.药品带量采购政策的利益相关者分析[J].卫生经济研究,2019,(08):8.
　SHU Qian,YAO Zheng-rong,WANG Yan-hui,et al.Stakeholder Analysis of Drug Consumption Policy[J].Journal Press of Health Economics Research,2019,(02):8.
[10]黎东生,白雪珊.带量采购降低药品价格的一般机理及“4+7招采模式”分析[J].卫生经济研究,2019,(08):10.
　LI Dong-sheng,BAI Xue-shan.The General Mechanism of Reducing the Price of Medicines by Quantity Purchase and the Analysis of “4+7 Recruitment Mode”[J].Journal Press of Health Economics Research,2019,(02):10.

更新日期/Last Update: 2019-01-29